Finasteride 2.5 mg (100 Tablets)

Protect Your Hairline

Finasteride is the single most effective defense against Androgenic Alopecia (Male Pattern Baldness). By inhibiting the 5-alpha reductase enzyme, it blocks the conversion of Testosterone into DHT—the primary hormone responsible for shrinking hair follicles.

Essential for men who want to maintain their hair density while on a cycle of high-testosterone compounds.

Key Benefits:

• Stops Hair Loss: Proven reduction in scalp DHT levels by up to 60%.
• Regrowth: Can stimulate regrowth in thinning areas.
• Economical: 100 x 2.5mg tablets offer huge value (tablets can be split).
• Prostate Health: Also supports prostate health by reducing DHT.

Dosage:

• Hair Loss: 1mg daily (half a tablet every other day is often sufficient with this 2.5mg dose).
• On Cycle: 1mg-2.5mg daily depending on compound dosage.

1. Description — Clinical summary

Finasteride 2.5 mg tablets is an oral 5-alpha reductase inhibitor. Finasteride is an FDA-approved medication for the treatment of benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss). In the context of anabolic steroid use, it is commonly employed as an ancillary compound to mitigate DHT-related hair loss caused by testosterone and other aromatizable steroids.

Key points:

• Active compound: finasteride, oral tablets.
• Dosage form: 100 tablets per pack, 2.5 mg per tablet.
• Mechanism: selectively inhibits Type II 5-alpha reductase, blocking conversion of testosterone to dihydrotestosterone (DHT).
• Approved medical indications: BPH (5 mg daily) and male pattern hair loss (1 mg daily).
• The 2.5 mg dosage allows flexible dosing between standard medical protocols.

2. How does finasteride work?

Mechanism of action — pharmacology summary:

• Selective 5-alpha reductase Type II inhibitor: Finasteride competitively and specifically inhibits the Type II isoenzyme of 5-alpha reductase, which is responsible for converting testosterone to DHT in the prostate, scalp, and other androgen-sensitive tissues.
• DHT reduction: Reduces serum DHT levels by approximately 70% at standard doses, and scalp DHT by approximately 60%.
• Hair follicle protection: By reducing DHT levels at the hair follicle, finasteride slows or reverses miniaturization of hair follicles in androgenetic alopecia.
• Prostate effects: Reduces prostate volume by decreasing intraprostatic DHT.
• Does not directly affect testosterone levels, though testosterone may increase slightly due to reduced conversion to DHT.
• Pharmacokinetics: Well-absorbed orally, half-life approximately 6-8 hours, though biological effects persist longer due to tight binding to the 5-alpha reductase enzyme.

3. Dosage — usage guidelines

A. Approved medical dosing:

• Androgenetic alopecia: 1 mg once daily (standard approved dose).
• Benign prostatic hyperplasia: 5 mg once daily.
• The 2.5 mg tablet can be split for lower doses if needed.

B. Common use with anabolic steroids (informational):

• Typical reported patterns: 0.5-2.5 mg daily during steroid cycles containing testosterone or other DHT-converting compounds.
• Often started before or concurrently with the steroid cycle.
• Not effective against DHT-derivative steroids (e.g., masteron, stanozolol) since these do not rely on 5-alpha reductase for their androgenic activity.

C. Important considerations:

• Effects on DHT reduction take 3-6 months to become apparent for hair loss.
• Discontinuation reverses benefits within 6-12 months.
• Women of childbearing age must not handle crushed or broken tablets due to teratogenic risk.

4. Side effects — common and rare adverse effects

A. Common adverse effects (1-10% incidence):

• Sexual dysfunction: decreased libido, erectile dysfunction, reduced ejaculate volume.
• These effects are typically reversible upon discontinuation.

B. Less common effects:

• Breast tenderness or gynecomastia (due to altered testosterone/DHT ratio).
• Depression and mood changes reported in some users.
• Testicular pain (rare).

C. Post-finasteride syndrome (controversial):

• Some patients report persistent sexual, neurological, and psychological side effects after discontinuation.
• This remains an area of active research and debate in the medical community.
• Patients should be counseled about this possibility before starting treatment.

D. Monitoring:

• Baseline and periodic PSA testing (finasteride reduces PSA by approximately 50%).
• Monitor for sexual side effects and mood changes.
• Liver function tests if used concurrently with hepatotoxic compounds.

5. Storage

• Store at controlled room temperature: 20-25°C (68-77°F). Brief excursions permitted between 15-30°C.
• Protect from light and moisture: keep in original packaging.
• Keep container tightly closed.
• Women who are or may become pregnant should not handle crushed or broken tablets due to potential absorption and risk to a male fetus.
• Keep out of reach of children.
• Dispose of unused tablets per local pharmaceutical disposal regulations.